SerImmune Scores $8M For Antibody Mapping

Santa Barbara-based SeriImmune, a developer of immune mapping technology, has raised $8M in a funding round to map out the human immune systems, according to the company. The funding was led by Illumina Ventures, and also included Merck and additional investors. The startup, led by CEO Patrick Daugherty, says it is developing immune mapping technology and a database of human antibodies which will help in identification of therapeutic and vaccine candidates. SerImmune says it maps the distinct antibodies within a repertoire to antigens associated with infections, allergens, microbiome organisms, autoimmune diseases, and cancers. More information »